Evotec SE: translational BRIDGE partnership beLAB2122 selects oncology project from Goethe University Frankfurt

  • Evotec SE announced today that a project has been selected for further development within beLAB2122, a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany to efficiently advance first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-translational-bridge-partnership-belab2122-selects-oncology-project-from-goethe-university-frankfurt-6191

    Du magst vielleicht auch